Thyroid FNAC cytology: can we do it better?
Thyroid FNAC cytology: can we do it better?
复制标题
甲状腺 FNAC 细胞学检查：我们能做得更好吗？
DOI：
10.1111/j.1365-2303.2007.00492.x
复制
发表时间：
2007
期刊：
影响因子：
1.3
通讯作者：
C. Yiangou
中科院分区：
文献类型：
--
作者：
D. Poller;E. Stelow;C. Yiangou
本文回顾了甲状腺细针抽吸细胞学 (FNAC) 的最新进展。虽然甲状腺结节很常见，但癌相对罕见。尽管大多数研究都使用组织学评估作为基准，但细胞学或组织学的鉴别诊断并不总是可重复的。文献显示甲状腺 FNAC 不足的标准以及研究纳入或排除标准存在很大差异。尽管临床甲状腺 FNAC 评估和报告的成本和资源影响很大，但甲状腺 FNAC 标本充足性的临床评估和临床报告已变得流行。尽管液基细胞学和超声引导 FNAC 越来越受欢迎，但许多中心仍在继续使用传统技术。 FNAC 报告的标准化分类系统可以使临床医生更容易理解结果，并为治疗行动提供明确的指示。多学科病例审查也很重要，尤其是在诊断不确定的情况下。虽然目前用途有限，但分子病理学测试为未来带来了一些希望。
This article reviews recent developments in thyroid fine needle aspiration cytology (FNAC). While thyroid nodules are common, carcinoma is comparatively rare. Although histological assessment is used in most studies as the benchmark, the differential diagnosis on cytology or histology is not always reproducible. The literature shows wide variations in criteria for inadequate thyroid FNAC and study inclusion or exclusion criteria. In‐clinic assessment of specimen adequacy and in‐clinic reporting of thyroid FNAC has become popular although the costs and resource implications of in‐clinic thyroid FNAC assessment and reporting are substantial. Many centres continue to use conventional techniques although liquid‐based cytology and ultrasound‐guided FNAC are gaining in popularity. Standardized categorical systems for FNAC reporting can make results easier to understand for clinicians and give clear indications for therapeutic action. Multidisciplinary case review is also essential, especially when there is diagnostic uncertainty. While currently of limited use, molecular pathology testing holds out some promise for the future.